Treating the underlying CTD is key to managing ILD in combination with anti-fibrotic. In the SENCIS study, patients on combination of MMF at baseline +Nintedanib had reduced decline in FVC compared to Nintedanib alone https://t.co/NmVRZ44JGE Paul Noble #ACR22 @RheumNow https://t.co/mulaBK61ga